Athero Review - Issue 3/2022
Editorial
127
Guidelines
130
Statement CSAT on Consensus EAS 2021: Triglyceride-rich lipoproteins and their remnants – metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies
Michal Vrablík, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, David Karásek, Pavel Kraml, Jan Piťha, Hana Rosolová, Vladimír Soška, Tomáš Štulc, Zuzana Urbanová Za Výbor Čsat, Jana Mašková
Reviews
140
Newer possibilities of slowing the development of chronic kidney disease and the role of dapagliflozin
Jan Vachek, Kateřina Oulehle, Hana Ciferská, Oskar Zakiyanov, Vladimír Tesař
147
Bempedoic acid – a new drug to lower LDL-cholesterol level
Vladimír Soška, Ondřej Kyselák
152
The importance of diet therapy and the correct regimen in familial hypercholesterolemia
Věra Boháčová, Tamara Starnovská
Clinical Studies
156
PACMAN-AMI trial: review of endpoints
Roman Margóczy
159
What have imaging studies with evolocumab yielded?
Tomáš Kovárník, Karel Kopřiva, Jan Pudil, Zhi Chen, Milan Šonka
Personal News
From International Literature
Announcements
169
XXXVI. konference o hyperlipoproteinemiích – Šobrův den 2022
Kristýna Čillíková
Athero Review
2022 Issue 3
Most read in this issue
- Bempedoic acid – a new drug to lower LDL-cholesterol level
- Newer possibilities of slowing the development of chronic kidney disease and the role of dapagliflozin
- Statement CSAT on Consensus EAS 2021: Triglyceride-rich lipoproteins and their remnants – metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies
- XXXVI. konference o hyperlipoproteinemiích – Šobrův den 2022